$1.87
Plus Therapeutics is a biotechnology business based in the US. Plus Therapeutics shares (PSTV) are listed on the NASDAQ and all prices are listed in US Dollars. Plus Therapeutics employs 20 staff and has a trailing 12-month revenue of around $6.1 million.
Our top picks for where to buy Plus Therapeutics stock
How to buy Plus Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PSTV. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Plus Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Plus Therapeutics stock price (NASDAQ: PSTV)
Use our graph to track the performance of PSTV stocks over time.Plus Therapeutics shares at a glance
Latest market close | $1.80 |
---|---|
52-week range | $0.97 - $3.21 |
50-day moving average | $1.98 |
200-day moving average | $1.83 |
Wall St. target price | $33.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.92 |
Is it a good time to buy Plus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Plus Therapeutics price performance over time
Historical closes compared with the close of $1.8 from 2024-07-25
1 week (2024-07-19) | 3.45% |
---|---|
1 month (2024-06-26) | 22.45% |
3 months (2024-04-26) | 6.51% |
6 months (2024-01-26) | -12.62% |
1 year (2023-07-26) | -32.33% |
---|---|
2 years (2022-07-26) | 256.44% |
3 years (2021-07-26) | 2.18 |
5 years (2019-07-26) | 10.385 |
Plus Therapeutics financials
Revenue TTM | $6.1 million |
---|---|
Gross profit TTM | $-9,474,000 |
Return on assets TTM | -69.96% |
Return on equity TTM | -522.5% |
Profit margin | -193.49% |
Book value | $-1.13 |
Market Capitalization | $9.9 million |
TTM: trailing 12 months
Plus Therapeutics share dividends
We're not expecting Plus Therapeutics to pay a dividend over the next 12 months.
Have Plus Therapeutics's shares ever split?
Plus Therapeutics's shares were split on a 1:15 basis on 30 April 2023. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Plus Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Plus Therapeutics shares which in turn could have impacted Plus Therapeutics's share price.
Plus Therapeutics share price volatility
Over the last 12 months, Plus Therapeutics's shares have ranged in value from as little as $0.97 up to $3.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Plus Therapeutics's is 0.537. This would suggest that Plus Therapeutics's shares are less volatile than average (for this exchange).
Plus Therapeutics overview
Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc.
Frequently asked questions
What percentage of Plus Therapeutics is owned by insiders or institutions?Currently 1.933% of Plus Therapeutics shares are held by insiders and 11.74% by institutions. How many people work for Plus Therapeutics?
Latest data suggests 20 work at Plus Therapeutics. When does the fiscal year end for Plus Therapeutics?
Plus Therapeutics's fiscal year ends in December. Where is Plus Therapeutics based?
Plus Therapeutics's address is: 4200 Marathon Boulevard, Austin, TX, United States, 78756 What is Plus Therapeutics's ISIN number?
Plus Therapeutics's international securities identification number is: US72941H4002 What is Plus Therapeutics's CUSIP number?
Plus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 72941H103
More guides on Finder
-
Options trading strategies for beginners
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question